预约演示
更新于：2026-02-27
Nicergoline
尼麦角林
更新于：2026-02-27
概要
基本信息
原研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H26BrN3O3 |
InChIKeyYSEXMKHXIOCEJA-FVFQAYNVSA-N |
CAS号27848-84-6 |
关联
32
项与 尼麦角林 相关的临床试验CTR20241708
健康成年受试者空腹和餐后状态下单次口服尼麦角林片的随机、开放、单剂量、四周期、完全重复交叉设计的生物等效性试验
CTR20234046
健康受试者餐后状态下单次口服尼麦角林片的生物等效性试验
CTR20233222
健康成年受试者空腹和餐后状态下单次口服尼麦角林片的生物等效性试验
100 项与 尼麦角林 相关的临床结果
登录后查看更多信息
100 项与 尼麦角林 相关的转化医学
登录后查看更多信息
100 项与 尼麦角林 相关的专利（医药）
登录后查看更多信息
533
项与 尼麦角林 相关的文献（医药）2026-01-01ANALYTICA CHIMICA ACTA
Development and validation of UPLC–MS/MS method for detecting nootropic misuse in oral fluids: A step towards combating doping in Esports
Article
作者: Salum, Kassim Ali ; Chen, Hung-Chih ; Chang, William Chih-Wei ; Hung, Shao-Hsin ; Hsieh, Meng-Tsang
BACKGROUND:
Esports, now officially recognised by the Olympic movement, requires effective anti-doping measures tailored to its unique performance demands. Traditional tests target substances enhancing strength or endurance, yet Esports performance is often influenced by nootropics or "smart drugs"-compounds improving focus, reaction time, and cognition. This study presents a validated sample preparation protocol and UPLC-MS/MS method for detecting nootropics of concern, including substances currently prohibited, under review, or potentially capable of enhancing Esports performance. Oral fluid is employed as a rapid, non-invasive specimen, offering a practical approach for doping control in Esports.
RESULTS:
Extraction and quantification of 13 nootropics and their metabolites in oral fluid, collected via self-administered oral swabs, were successfully optimised. Solid-phase extraction yielded the highest recoveries for analytes across a wide range of physicochemical properties, outperforming both dilute-and-shoot and supported liquid extraction approaches. The analytes were separated within 4 min using a UPLC BEH C18 column. The analytical method was fully validated, demonstrating good precision, accuracy, and lower quantification limits ranging from 0.01 to 50 ng/mL. Most analytes remained stable for one day at room temperature, three days under refrigeration, and one month when frozen. Oral fluid sampling proved effective in detecting nootropics in authentic volunteer samples for up to 4 h post-administration. Detected concentrations included pentoxifylline (7.9-97.2 ng/mL), piracetam (2.8-215.2 μg/mL), and nicergoline (as its main metabolite; 0.6-5.3 ng/mL). Variability in concentrations was influenced by swab positioning and food intake prior to sampling.
SIGNIFICANCE:
This study establishes a robust and practical analytical method utilising oral fluid for the detection of nootropics relevant to doping control in Esports. The approach enables rapid, non-invasive sample collection and reliable quantification, offering the potential for routine pre-game and in-competition monitoring. While the method is validated, further investigation is warranted to define drug excretion profiles and detection windows in oral fluid under real-use conditions.
2024-12-01SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
Medications to Modify Aspiration Risk: Those That Add to Risk and Those That May Reduce Risk
Review
作者: Gonçalves-Pereira, João ; Froes, Filipe ; Mergulhão, Paulo
Abstract:
Aspiration pneumonia results from the abnormal entry of fluids into the respiratory tract. We present a review of drugs known to affect the risk of aspiration. Drugs that increase the risk of aspiration pneumonia can be broadly divided into those that affect protective reflexes (like cough and swallowing) due to direct or indirect mechanisms, and drugs that facilitate gastric dysbiosis or affect esophageal and intestinal motility. Chief among the first group are benzodiazepines and antipsychotics, while proton pump inhibitors are the most well-studied in the latter group. Pill esophagitis may also exacerbate swallowing dysfunction. On the other hand, some research has also focused on pharmaceutical modulation of the risk of aspiration pneumonia. Angiotensin-converting enzyme inhibitors have been demonstrated to be associated with a decrease in the hazard of aspiration pneumonia in high-risk patients of Chinese or Japanese origin. Drugs like amantadine, nicergoline, or folic acid have shown some promising results in stroke patients, although the available evidence is thus far not enough to allow for any meaningful conclusions. Importantly, antimicrobial prophylaxis has been proven to be ineffective. Focusing on modifiable risk factors for aspiration pneumonia is relevant since this may help to reduce the incidence of this often severe problem. Among these, several commonly used drug classes have been shown to increase the risk of aspiration pneumonia. These drugs should be withheld in the high-risk population whenever possible, alongside general measures, such as the semirecumbent position during sleep and feeding.
2024-03-08ACS infectious diseases
Dronedarone Enhances the Antibacterial Activity of Polymyxin B and Inhibits the Quorum Sensing System by Interacting with LuxS
Article
作者: Wang, Xiao ; Zhang, Jinyong ; Zou, Quanming ; Cui, Ruiqin ; Zhou, Fan ; Huang, Wei ; Liu, Xiaodi ; Hu, Chunxia ; Zhang, Min
Quorum sensing (QS) is considered an appealing target for interference with bacterial infections. β-Adrenergic blockers are promising anti-QS agents but do not have antibacterial activity. We assessed the potential ability of adrenergic receptor inhibitors to enhance the antibacterial activity of polymyxin B (PB) against Klebsiella pneumoniae and determined that dronedarone has the most potent activity both in vitro and in vivo. We found that dronedarone increases the thermal stability of LuxS, decreases the production of AI-2, and affects the biofilm formation of K. pneumoniae. We also identified the direct binding of dronedarone to LuxS. However, the mechanism by which dronedarone enhances the antibacterial activity of PB has not been elucidated and is worthy of further exploration. Our study provides a basis for the future development of drug combination regimens.
100 项与 尼麦角林 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 头晕 | 中国 | 2000-12-15 | |
| 智力障碍 | 中国 | 2000-12-15 | |
| 情绪障碍 | 中国 | 1999-09-17 | |
| 外周血管疾病 | 中国 | 1999-09-17 | |
| 动脉硬化 | 韩国 | 1978-12-16 | |
| 脑梗塞 | 韩国 | 1978-12-16 | |
| 痴呆 | 韩国 | 1978-12-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阿尔茨海默症 | 临床3期 | 美国 | - | |
| 精神病性情感障碍 | 临床1期 | 中国 | 2020-04-30 | |
| 血管性痴呆 | 临床1期 | 中国 | 2020-04-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用